EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Endogenous Glucagon-Like Peptide 1 Enhanced by Vildagliptin Reduces Triglyceride Appearance During Intraduodenal Fat Infusion in Type 2 Diabetes

Cong Xie iD, Jake B White, Weikun Huang iD, Michael Horowitz, Christopher K Rayner iD, Johan W Verjans, Marten F Snel, Peter J Psaltis, Tongzhi Wu iD

Diabetes · 2026

DOI: 10.2337/db25-0980 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, 2026. Verfasst von Cong Xie und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, College of Health, Adelaide University, Adelaide, South Australia, Australia. Hauptthemen laut MEDLINE: Adamantane, Diabetes Mellitus, Type 2, Dipeptidyl-Peptidase IV Inhibitors, Glucagon-Like Peptide 1. Gefördert von: National Heart Foundation of Australia, Novartis Australia, Central Adelaide Local Health Network.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glucagon-like peptide 1 (GLP-1) receptor agonists improve dyslipidemia and reduce cardiovascular risk in type 2 diabetes (T2D), but the role of endogenous GLP-1 in lipid metabolism remains unclear. We evaluated the effect of dipeptidyl peptidase 4 (DPP-4) inhibition on the response of plasma triglycerides (TGs) to intraduodenal lipid and a mixed meal, and the impact of GLP-1 receptor blockade with exendin(9-39) in T2D. Fifteen participants with T2D, managed by diet and/or metformin, were studied on three occasions in a double-blind, randomized, crossover design. Vildagliptin (50 mg) or placebo was administered orally (t = −60 min), followed by intravenous exendin(9-39) from t = −60 to 150 min on one of the two vildagliptin days or 0.9% saline on two other days. A lipid emulsion was infused intraduodenally (2 kcal/min, t = 0–120 min), followed by a mixed meal (t = 120–150 min). Plasma TG levels, quantified by liquid chromatography-tandem mass spectrometry, increased after lipid and meal, with most individual TGs corresponding to those in the lipid emulsion. Vildagliptin reduced TG(54:4) and TG(54:5) concentrations (each P < 0.01), without affecting total TGs. Blocking endogenous GLP-1 during vildagliptin treatment increased plasma total TGs (P < 0.001), associated with elevations of 10 individual TG species (P < 0.05 each). These outcomes suggest that endogenous GLP-1 contributes to the physiological modulation of postprandial TG appearance in T2D. Article Highlights The contribution of endogenous glucagon-like peptide 1 (GLP-1) to postprandial lipid metabolism in type 2 diabetes (T2D) is poorly defined. The specific questions we wanted to answer were what is the effect of dipeptidyl peptidase 4 (DPP-4) inhibition on plasma triglyceride (TG) profiles during an intraduodenal lipid infusion and following a mixed meal in T2D, and how does blockage of endogenous GLP-1 signaling affect these responses? We found that plasma TGs increased after intraduodenal lipid infusion and the meal, with most species reflecting the infused lipid emulsion. Vildagliptin selectively reduced TG(54:4) and TG(54:5) species, whereas exendin(9-39) increased total TGs and 10 individual TG species. The implications of our finding are that endogenous GLP-1 plays a physiological role in the regulation of postprandial lipid handling in T2D.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdamantaneDiabetes Mellitus, Type 2Dipeptidyl-Peptidase IV InhibitorsGlucagon-Like Peptide 1TriglyceridesVildagliptinAgedFemaleHumansMaleMiddle AgedCross-Over StudiesDouble-Blind MethodDuodenumHypoglycemic AgentsNitrilesPeptide FragmentsPyrrolidines

Substanzen

AdamantaneDipeptidyl-Peptidase IV Inhibitorsexendin (9-39)Glucagon-Like Peptide 1Hypoglycemic AgentsNitrilesPeptide FragmentsPyrrolidinesTriglyceridesVildagliptin

Autor:innen und Institutionen

  • School of Medicine, College of Health, Adelaide University, Adelaide, South Australia, Australia.
  • Centre of Research in Translating Nutritional Science to Good Health, Adelaide University, Adelaide, South Australia, Australia.
  • Endocrine and Metabolic Unit, Royal Adelaide Hospital, Adelaide, South Australia, Australia.
  • Lifelong Health Theme, South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia.
  • Department of Gastroenterology and Hepatology, Royal Adelaide Hospital, Adelaide, South Australia, Australia.
  • Mass Spectrometry Facility, South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia.

ORCID-Profile: Cong Xie, Weikun Huang, Christopher K Rayner, Tongzhi Wu

Förderung

  • National Heart Foundation of Australia
  • Novartis Australia
  • Central Adelaide Local Health Network
  • Australian Medical Research Future Fund
  • Michell Bequest Foundation

Zitieren

APA

Xie, C., White, J. B., Huang, W., Horowitz, M., Rayner, C. K., Verjans, J. W., Snel, M. F., Psaltis, P. J., & Wu, T. (2026). Endogenous Glucagon-Like Peptide 1 Enhanced by Vildagliptin Reduces Triglyceride Appearance During Intraduodenal Fat Infusion in Type 2 Diabetes. Diabetes. https://doi.org/10.2337/db25-0980

Vancouver

Xie C, White JB, Huang W, Horowitz M, Rayner CK, Verjans JW, et al. Endogenous Glucagon-Like Peptide 1 Enhanced by Vildagliptin Reduces Triglyceride Appearance During Intraduodenal Fat Infusion in Type 2 Diabetes. Diabetes. 2026. doi:10.2337/db25-0980

BibTeX
@article{Xie2026,
  author = {Xie, Cong and White, Jake B and Huang, Weikun and Horowitz, Michael and Rayner, Christopher K and Verjans, Johan W and Snel, Marten F and Psaltis, Peter J and Wu, Tongzhi},
  title = {Endogenous Glucagon-Like Peptide 1 Enhanced by Vildagliptin Reduces Triglyceride Appearance During Intraduodenal Fat Infusion in Type 2 Diabetes},
  journal = {Diabetes},
  year = {2026},
  doi = {10.2337/db25-0980}
}
Kostenlos starten →